Attitudes toward COVID-19 Vaccination: Staff and Patient Perspectives at Six Health Facilities in Sierra Leone
by
, , , ,
on behalf of the Cross-Site COVID-19 Cohort Technical Group
Stefanie A. Joseph
1,*,†,
Jean Gregory Jerome
2,†, 
Foday Boima
2,
Pierre Ricard Pognon
2,
Donald Fejfar
1,
Yusupha Dibba
2,
Daniel Lavalie
3,
Mohamed Bailor Barrie
2,
Aramide Oteju
2,
Mohamed Sheku
2,
Mariama Mahmoud
3,
Jusu Mattia
3 and
Dale A. Barnhart
1,4,‡
on behalf of the Cross-Site COVID-19 Cohort Technical Group 1
Partners In Health (PIH), Boston, MA 02199, USA
2
Partners In Health Sierra Leone (PIH-SL), Freetown, Sierra Leone
3
Ministry of Health and Sanitation, Freetown, Sierra Leone
4
Harvard Medical School, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
Member names are provided in the Acknowledgements.
Vaccines 2023, 11(8), 1385; https://doi.org/10.3390/vaccines11081385
Submission received: 23 June 2023
/
Revised: 8 August 2023
/
Accepted: 16 August 2023
/
Published: 19 August 2023
(This article belongs to the Special Issue Attitudes and Perspectives toward COVID-19 Vaccines)
Abstract
:Sierra Leone is a West African country with a population of over 8 million. With more than half of Sierra Leone’s population living in rural areas, it is important to understand rural populations’ access to and attitudes toward the COVID-19 vaccine. In November 2021, the rate of vaccination coverage in Sierra Leone was only 7% for one dose and 4% for two doses. Understanding perspectives of health facility staff and patients can help strengthen future vaccine campaigns. We conducted a cross-sectional study, between March 2022 and May 2022, of clinical staff, non-clinical staff, and adult (>18 years) patients/caregivers attending six Ministry of Health and Sanitation (MoHS) facilities supported by Partners In Health, four in the Kono district and two in the Western Urban Area district, the capital of Sierra Leone. We assessed the opportunity to vaccinate, vaccine uptake, and intention to vaccinate. Out of the 2015 participants, 11.4% were clinical staff, 18.8% were non-clinical staff, and 69.8% were patients/caregivers. Less than half of the patients/caregivers had the opportunity to be vaccinated (42%), and 22% of patients/caregivers were fully vaccinated. Among the unvaccinated population, 44% would refuse a vaccine if offered to them at no cost. Lack of access to COVID-19 vaccines and to official education messaging, especially for patients and caregivers, is still an underlying problem in Sierra Leone for vaccine uptake, rather than a lack of willingness to be vaccinated.
1. Introduction
As of 24 May 2023, there have been 766,895,075 cases and 6,935,889 deaths globally due to COVID-19 [1]. Sierra Leone recorded its first case/emergency in March 2020, with 7762 cases, 125 deaths, and 7,548,308 vaccine doses administered since [2], although these statistics may be underreported due to a lack of testing found in many low- and middle-income countries (LMICs). In Sierra Leone, many pre-existing factors have challenged the country’s ability to respond to the COVID-19 pandemic, including limited access to health care and preventative public health measures in rural areas [3].
While the COVID-19 vaccine has proven to be an effective tool for controlling the pandemic and preventing severe illness [4], this rollout was initially more accessible for high-income countries where strong economic conditions and high levels of education expedite the process [5,6]. COVID-19 vaccination campaigns could bolster the ability of health systems in Sierra Leone and other LMICs to curb the pandemic. To date, a lack of financing and equal access to vaccines among LMICs have limited the availability of COVID-19 vaccines in Sierra Leone [7,8,9,10]. However, trust in vaccines as well as the institutions that administer them is a key determinant of the success of any vaccination campaign [11]. Consequently, as COVID-19 vaccines become more available in Sierra Leone, vaccine uptake and intention to vaccinate will become key factors that will dictate the effectiveness of vaccination campaigns.
Although COVID-19 vaccines have been demonstrated to be extremely effective [4], the poor uptake of vaccines in high-income settings has already become a major barrier to the global COVID-19 response [11,12,13]. Initial studies suggested that select low-income countries had similar attitudes toward COVID-19 vaccines as high-income settings, but vaccine hesitancy is a complex and context-specific phenomenon that evolves [14,15,16]. As COVID-19 vaccines become more widely available in LMICs, additional research is needed to understand context-specific factors that may affect uptake, especially research that is focused on rural areas where the population may have less access to education, mass media, and health care [17]. To date, few studies have assessed vaccine hesitancy in Sierra Leone [18,19,20]. To better inform ongoing vaccination campaigns, including communications and outreach efforts in Sierra Leone, this study aimed to assess the current attitudes and perceptions of COVID-19 vaccines for individuals living in the Kono district and Western Urban Area district, Sierra Leone.
2. Materials and Methods
2.1. Study Setting
Sierra Leone is a West African country that is among the poorest in the world, with about 57% of its more than 8 million residents living below the poverty line today [21,22]. Its health system is recovering after two major crises — an 11-year civil war and the Ebola epidemic — while also growing in order to reduce the overall burden of maternal mortality, malnutrition, infectious diseases, non-communicable diseases, and chronic conditions [23,24]. Partners In Health (PIH) is a non-profit organization that works with the Ministry of Health and Sanitation (MoHS) on health systems to strengthen activities in the Kono district and Western Urban Area district, Sierra Leone. Activities include the provision of direct clinical care, clinical and community health worker training, supply chain system support, and innovative clinical interventions to improve patient outcomes and build health care delivery systems. Currently, PIH supports health care services in the Kono district (Koidu Government Hospital, Wellbody Clinic, Sewafe Community Health Center, and Kombayendeh Community Health Center) and in the Western Urban Area district (Lakka Government Hospital and Kissy Psychiatric Teaching Hospital) in Freetown.
This study was conducted in six MoHS health facilities. Four facilities (Koidu Government Hospital, Wellbody Clinic, Sewafe Community Health Center, and Kombayendeh Community Health Center) are in the Kono district, an eastern region district with a catchment population of 506,100 people [25], 75% of whom live in rural areas [26]. Two facilities (Lakka Government Hospital and Kissy Psychiatric Teaching Hospital) are in the Western Urban Area district in Freetown, Sierra Leone, a major urban, economic, cultural, educational, and political center with a population of more than one million people [25]. PIH has been supporting MoHS services in these facilities since 2015.
2.2. Study Design and Study Population
A convenience sampling method was used to gather data on as many participants as available during the study collection period. We recruited adult patients over 18 years of age or accompanying adult caregivers who were waiting in the various outpatient departments. Any patient who was in medical distress or not mentally capable of providing consent was excluded from the study.
Clinical and non-clinical staff in facilities were also eligible to participate. In order to estimate the proportion of respondents who would be willing to be vaccinated with a 95% confidence interval of +/−3%, we estimated our target sample size should be 1000. This sample size calculation assumes that the proportion of respondents who are willing to be vaccinated is similar to what has been previously observed in PIH-supported populations in Haiti and Malawi (approximately 25%). However, depending on respondent availability, we anticipated that actual enrollment could range from 500 (precision of +/−4%) to 2500 individuals (precision of +/−2%).
2.3. Data Collection
Data was collected from 29 March 2022 to 11 May 2022. Enumerators fluent in Krio verbally administered a 15-to-25-minute questionnaire in Krio focused on vaccination status, intention to vaccinate, attitudes toward the COVID-19 vaccine, and sources of information about the COVID-19 vaccine. Non-identifiable demographic characteristics, such as age, sex, ethnicity, education, facility location, and role at the facility, were also collected. Data was collected electronically using tablets and the CommCare app.
All study staff that engaged in data collection received a two-day training in research ethics, including respect for study participants, consent procedures, and secure storage and maintenance of data before the start of the evaluations. Additionally, they received survey-specific training during the study period.
2.4. Data Analysis
Vaccine uptake was defined as whether or not a person received a COVID-19 vaccine and reflected vaccine access along with willingness to be vaccinated [27]. Vaccination status was broken down into multiple categories: (1) opportunity to be vaccinated defined as ever having the opportunity to receive a vaccine for COVID-19; (2) received vaccine or partially vaccinated meaning receiving at least one dose of a COVID-19 vaccine; (3) fully vaccinated as in receiving both doses of a COVID-19 vaccine or one dose if the vaccine manufacturer was Johnson & Johnson; and (4) not vaccinated as in not having the opportunity to be vaccinated or refused to receive the vaccine. Intention to vaccinate was defined as whether or not a person would receive a vaccine if it were made available to them today at no cost [27].
Additionally, we assessed attitudes of COVID-19 by intention to vaccinate, trusted sources of COVID-19 information, and quality of care at the vaccination site. Responses were compared among vaccination statuses. Participants reported their trust in a source using a 5-point Likert Scale, ranging from “strongly distrust” to “trust a lot” options. All survey questions are available in Appendix A.
Participants were asked open-ended questions as to why they refused vaccination, reasons they would or would not be willing to receive the COVID-19 vaccine, and their primary sources of COVID-19 information. After hearing their responses, enumerators would code them into synonymous pre-defined categories. If a response did not fit into one of these categories, there was an option to select “Other” and provide a write-in response. Categories were developed based on previous survey tools on attitudes toward the COVID-19 vaccine [11,15,27,28]. Reasons for and against vaccination were observed among clinicians, non-clinicians, outpatients, and caregivers.
Data was analyzed using STATA 15.1 [29]. The statistical analysis consisted primarily of descriptive statistics, with data summarized using frequencies, percentages, and bar graphs. Chi-squared or Fisher’s exact tests were used to assess the associations between demographic characteristics and outcomes of interest. Univariate and multivariate logistic regressions were conducted to assess predictors of low access (having no opportunity to be vaccinated) and predictors of non-acceptance (responded no or unsure to the intention of receiving a COVID-19 vaccine). Backward stepwise regression was used to eliminate variables from the full model. The full model was reduced until all demographic variables had a p < 0.05.
2.5. Ethical Considerations
The study obtained ethical approval on 27 January 2022 from the PIH Sierra Leone Research and Ethic Committee and the Sierra Leone Ethics and Scientific Review Committee, IRB# 1.0, before the start of data collection. All data was stored securely and anonymously.
3. Results
A total of 2015 participants completed the questionnaire, 230 (11.4%) clinicians, 379 (18.8%) non-clinical staff, and 1406 (69.8%) outpatients or patient caregivers (Table 1). A majority of the study population was enrolled at the Koidu Government Hospital (30.6%) or Wellbody Clinic (25.9%), 51.6% were women, and 1736 participants (86.2%) were less than 45 years old. More than half of the respondents completed education higher than primary school, with 81.3% of clinicians completing post-secondary education and 33.1% of outpatients or patient caregivers having received no formal education. Individuals mostly identified with being Kono (n = 771, 38.3%) or Krio (n = 562, 27.9%). All three groups cited that mass media was their primary source of COVID-19 vaccine information, with clinicians and staff being more likely to cite social media, the national government, or the Ministry of Health (MoH) as a primary source, while outpatients or patients’ caregivers chose their family or friends as a primary source. Location of the study interview, sex, age, level of education, identifying as Kono, Mende, or Mandingo, and all primary sources of COVID-19 vaccine information were significantly associated (p < 0.05) with the respondents’ role at the facility.
Figure 1a shows a bar graph of COVID-19 vaccine uptake by facility role. Clinical (n = 183, 80%) and non-clinical staff (n = 254, 67%) reported having more opportunities to receive the vaccine compared to outpatients/patient caregivers (n = 592, 42%), p < 0.001. Most staff members were fully vaccinated; however, only 22% of all outpatients/caregivers received complete dosages. Figure 1b presents a bar graph of the intention to vaccinate by facility role. Overall, the intention to vaccinate was high in all three groups, although it was the highest among clinicians (82%) and lowest among the patients/caregivers (70%).
Actual vaccination status was associated with willingness to be vaccinated in a hypothetical situation where a vaccine was offered today at no cost (Table 2). Over 95% of those who were fully vaccinated would say “Yes” to an approved COVID-19 vaccine if it were offered to them today at no cost. Among those who were not vaccinated, only 53.8% were willing to be vaccinated. Out of all the vaccine types listed, individuals were more willing to receive AstraZeneca (55.9%) or Johnson & Johnson (55.3%). In general, participants chose the MoHS, local leaders, and family or friends as trusted sources to relay information about the COVID-19 vaccine. However, the vaccinated and partially vaccinated were more likely to cite these sources than the not vaccinated. In contrast, the not vaccinated were more likely to cite social media as a primary source. When participants discussed the quality of care during vaccination, partially vaccinated people reported a lower quality of care compared to those who were fully vaccinated.
Figure 2 presents reasons for and against vaccination among facility roles. More than 90% of all facility roles reported “For my health” as a reason for vaccination. A high proportion of staff supported COVID-19 vaccination recommendations by the government and mandates by their workplaces. Perceived benefits such as “For the health of my family” and “For the health of my community” were more commonly cited among outpatients and patient caregivers than clinical and non-clinical staff. Among those who would refuse or were unsure about a COVID-19 vaccine, more than 60% reported “Personally not at risk” and “Distrusts vaccine manufacturers” as reasons against vaccination. Compared to staff, outpatients and patient caregivers were significantly more likely to report “COVID-19 is not dangerous”, “Vaccine was designed to harm me”, “Religion beliefs”, and “Concerns about specific vaccine types” as reasons for being unwilling to receive the COVID-19 vaccine.
Additionally, we reported predictors of low access to COVID-19 vaccines (Table 3). About 49% of participants reported having no opportunity to be vaccinated. There were meaningful differences (p < 0.05) between those who had an opportunity to be vaccinated and those who did not in terms of location, role at the facility, sex, age, level of education, and all primary sources of COVID-19 information. Significant differences in vaccine accessibility could also be observed among those who identified as Kono, Krio, Temne, Limba, Fullah, and Loko. In the multivariate analysis, better vaccine access could be seen among those who identified as Kono (OR: 0.71; 95% CI; 0.56–0.91; p = 0.006) and received COVID-19 information from mass media (OR: 0.71; 95% CI: 0.54–0.92; p = 0.011), social media (OR: 0.74; 95% CI: 0.58–0.93; p = 0.011), and health care workers (OR: 0.44; 95% CI: 0.34–0.56; p < 0.001). Key predictors of low vaccine access included participating at Kissy Psychiatric Teaching Hospital (OR: 8.37; 95% CI: 4.89–14.33; p < 0.001) or Lakka Government Hospital (OR: 6.45; 95% CI:3.76–11.06; p < 0.001), being an outpatient or patient caregiver (OR: 4.21; 95% CI: 2.62–6.77; p < 0.001), being younger (OR: 4.62; 95% CI: 3.09–6.93; p < 0.001), and having a lower level of education (OR: 3.00; 95% CI: 1.98–4.55; p < 0.001).
Lastly, we analyzed the predictors of vaccine hesitancy (Table 4). Five hundred and thirty-five participants (27.1%) reported “No” or “Unsure” when presented with a hypothetical situation where a vaccine was offered today at no cost and were considered vaccine hesitant. In our univariate analysis, the following demographics were significantly different when comparing those who did and did not intend to be vaccinated: location, level of education, identifying as Kono, Krio, Temne, or Fullah, and receiving their primary source of COVID-19 information from mass media, family or friends, the national government or MoH, social media, health care workers, or an employer. In the multivariate analysis, predictors of vaccine hesitancy included participating at Kissy Psychiatric Teaching Hospital (OR: 32.90; 95% CI: 13.78–78.58; p < 0.001) or Lakka Government Hospital (OR: 26.37; 95% CI: 10.77–64.58; p < 0.001), being younger (OR: 1.98; 95% CI: 1.29–3.06; p = 0.009), having a lower level of education (OR: 3.16; 95% CI: 2.18–4.57; p < 0.001), and identifying as Krio (OR: 2.97; 95% CI: 2.20–4.01; p < 0.001). Individuals who reported obtaining COVID-19 information from mass media (OR: 0.65; 95% CI: 0.50–0.85; p = 0.002) and health care workers (OR: 0.31; 95% CI: 0.23–0.42; p < 0.001) had lower odds of vaccine hesitancy.
4. Discussion
Overall, our study found low access to vaccines but high willingness to be vaccinated among patients and caregivers at hospitals in Sierra Leone. Only 42% of patients/caregivers reported having previous opportunities to be vaccinated, and 22% were fully vaccinated. However, 70% of patients and caregivers and 54% of the currently unvaccinated were willing to be vaccinated if a vaccine were provided to them for free. This level of vaccine acceptance is much higher than what was previously reported in a systematic review of African studies showing a vaccine acceptance rate of 49% [30]. There are various possible explanations for this finding. First, the high level of intention to be vaccinated may be associated with the post-Ebola outbreak context in Sierra Leone, leading people to be more receptive to public health messages about disease outbreaks than other populations. Second, a preparedness strategy against an Ebola outbreak at the Guinea borders with the Kono district coincided with the vaccine campaign for COVID-19, and this could have resulted in willingness to be vaccinated being substantially higher in the Kono district than in other hospitals. As a result, and due to the fear associated with the resurgence of an Ebola outbreak, respondents may have had this in mind when responding about their attitudes toward COVID-19 vaccines. Additionally, due to the severity and urgency of patients’ conditions at specialty hospitals, vaccination may not be the highest priority, therefore demonstrating poor vaccine outcomes at Lakka Government Hospital and Kissy Psychiatric Teaching Hospital.
Unsurprisingly, our data showed significant differences between respondents with a facility role (clinical and non-clinical staff) compared to patients/caregivers. Respondents with facility roles were more likely to have had the opportunity to receive the vaccine, to be fully vaccinated, and to exhibit a willingness to be vaccinated in the future. This difference may have been associated mainly with the adopted strategy to prioritize people with facility roles during the first rounds of COVID-19 vaccine campaigns, as they were considered to be of higher risk [30]. This may also be explained by the fact that respondents with a facility role were more likely to have a higher level of education. Lower access to COVID-19 vaccines among younger populations could be similarly explained by a strategy to prioritize the elderly.
High intention to vaccinate among health care workers (82%) may be due to attending both PIH and MoHS sensitization sessions at the beginning of the pandemic, where they were educated about the COVID-19 vaccine and disease. Patients and caregivers, on the other hand, were not offered the same opportunities to gain information or lessen their concerns. Intention to vaccinate may also be high due to the Ebola outbreak in Sierra Leone, inclining people to listen to public health messages about disease outbreaks and follow preventive measures to protect themselves and their family. This claim was further supported through our study, as 90% of facility roles mentioned the protection of their own health as a reason to accept the COVID-19 vaccine, and greater than 65% of clinical and non-clinical staff listed recommendations by the government as a reason for vaccine intent. The study also showed that the MoHS, local leaders, and family or friends are generally the most trusted among those fully and partially vaccinated or even unvaccinated, showing how people have built confidence in their leaders to make the right decisions to protect their health and that of their family and their community.
A limitation of our study was that it was only conducted in MoHS facilities supported by PIH, where this organization facilitates COVID-19 vaccine campaigns and messaging. PIH has also been involved in holding sensitization sessions with staff, resulting in positive change in staff perception and attitudes toward the COVID-19 vaccine. Future studies can compare PIH-supported MoHS facilities to non-PIH-supported MoHS facilities to understand how PIH’s efforts impacted our findings.
The study design also included a convenience sampling method; therefore, our study population may not be representative of the general public. Being that the study took place within health care facilities, social desirability bias may also play a role, i.e., participants could have answered in a manner that is favorable toward facility regulations.
Despite these limitations, our study points to several potentially modifiable strategies that could be used to improve the access to and uptake of vaccines. These include assigning community members or health facility staff as ambassadors to promote vaccination, increasing vaccine availability in specialty and teaching hospitals, creating outreach materials to be accessible in multiple languages, informing individuals throughout the vaccine process (type received, timing of second dose), and spreading educational messages through social media.
5. Conclusions
In the settings where the study was conducted in Sierra Leone, despite low availability of the vaccines for the targeted population, vaccine hesitancy remained relatively low among the respondents, especially among the respondents who were staff members at the facilities studied. This indicated that the lack of access to vaccines and to official education messaging, rather than lack of willingness to be vaccinated, is the primary barrier to successful COVID-19 vaccine campaigns in Sierra Leone. Therefore, efforts should be concentrated around tackling these issues to reach populations beyond health facility staff.
Author Contributions
Conceptualization: J.G.J., F.B., D.F., Y.D., D.L., M.B.B., A.O., M.S., M.M., J.M. and D.A.B.; methodology: J.G.J., F.B., P.R.P. and D.A.B.; software: S.A.J., F.B., P.R.P. and D.A.B.; validation: S.A.J., F.B. and D.A.B.; formal analysis: S.A.J. and D.A.B.; investigation: F.B.; writing—original draft preparation: S.A.J. and J.G.J.; writing—review and editing: S.A.J., J.G.J., F.B., P.R.P., D.F., Y.D., D.L., M.B.B., A.O., M.S., M.M., J.M. and D.A.B.; visualization: S.A.J. and D.A.B.; supervision: F.B. and P.R.P. All authors have read and agreed to the published version of the manuscript.
Funding
Made possible by the support of Wagner Foundation (project code AVA0251). Dale A. Barnhart is supported by the Harvard Medical School Global Health Equity Research Fellowship, funded by Jonathan M. Goldstein and Kaia Miller Goldstein.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and was approved by the PIH Sierra Leone Research Review Committee and the Sierra Leone Ethics and Scientific Review Committee (IRB#: 1.0; date of approval: 27 January 2022).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study. Participants were guided through oral informed consent before data collection. We received permission to obtain oral rather than written consent because the data collection tool did not gather any personally identifying information, and therefore, the signed consent form would have been the only item that could have linked individuals to the study.
Data Availability Statement
The data presented in this study are available upon request from the corresponding author and pending approval from the PIH Sierra Leone Research Review Committee.
Acknowledgments
Made possible by the support of Wagner Foundation. Special thanks to the Cross-Site COVID-19 Cohort Technical Working Group, study enumerators, and the Sierra Leone Ministry of Health and Sanitation, specifically Daniel Lavalie, Mariama Mahmoud, Jusu Mattia, and Mohamed Sheku. The Cross-Site COVID-19 Cohort Technical Working Group is composed of the following members: Partners In Health/Boston: Jean Claude Mugunga, Donald Fejfar, Stefanie A. Joseph; Partners In Health/Haiti: Wesler Lambert, Mary Clisbee, Fernet Leandre; Partners In Health/Liberia: Prince F. Varney; Partners In Health/Lesotho: Melino Ndayizigiye, Patrick Nkundanyirazo, Afom Andom; Partners In Health/Malawi: Emilia Connolly, Chiyembekezo Kachimanga, Fabien Munyaneza; Partners In Health/Mexico: Zeus Aranda; Partners In Health/Peru: Jesus Peinado, Marco Tovar; Partners In Health/Rwanda: Vincent Cubaka, Nadine Karema; Partners In Health/Sierra Leone: Foday Boima, Gregory Jerome; Harvard Medical School: Bethany Hedt-Gauthier, Isabel Fulcher, Dale Barnhart, Megan Murray.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Appendix A
- Vaccine Hesitancy Questionnaire
- 1.
- Have you ever had the opportunity to receive a vaccine for COVID-19?
- Yes
- No
- 2.
- [V1 = YES] Have you ever received a vaccine for COVID-19?
- Yes
- No
- 2a.
- [V2 = YES] Which COVID-19 vaccine did you receive?
- AstraZeneca/Oxford
- Pfizer/BioNTech
- Moderna
- Johnson & Johnson/Janssen
- Sinopharm/Chinese National Biotech Group
- Do not know
- 2b.
- [V2a! = Johnson & Johnson] Have you received two doses of the COVID-19 vaccine?
- Yes
- No
- Do not know
- 2c.
- [V2 = YES] When you received the first dose of your vaccine, did anyone tell you which type of vaccine you would receive?
- Yes
- No
- 2d.
- [V2 = YES] When you received the first dose of your vaccine, did anyone tell you the timing for your second dose?
- Yes
- No
- 2e.
- [V2 = YES] When you received the first dose of your vaccine, did anyone tell you about possible adverse events following immunization?
- Yes
- No
- 2f.
- [V2 = YES] When you received the first dose of your vaccine, were COVID-19 prevention measures maintained at the vaccination site?
- Yes
- No
- 2g.
- [V2 = YES] How satisfied were you with vaccination process?
- Very dissatisfied
- Dissatisfied
- Neutral
- Satisfied
- Very satisfied
- 3.
- [V2 = NO] Why did you not receive COVID-19 vaccine when it was offered to you? Select all that are mentioned. Do not read specific items, but you can prompt the respondent with “Any other reasons?”
- Logistic concerns
- ☐
- No transport
- ☐
- Too expensive
- Perceived risk of COVID-19
- ☐
- COVID-19 is not dangerous or does not exist
- ☐
- I am not personally at risk of COVID-19
- ☐
- I have already been infected with COVID-19
- COVID-19 vaccine
- ☐
- The COVID-19 vaccine is unsafe or has side effects
- ☐
- The COVID-19 vaccine has not been tested enough
- ☐
- The COVID-19 vaccine is not effective at stopping infection
- ☐
- The COVID-19 vaccine is specifically designed to harm me (e.g., conspiracy theory)
- ☐
- I have concerns about specific type(s) of COVID-19 vaccine
- Trust and Beliefs
- ☐
- Lack of trust in national government
- ☐
- Lack of trust in international donors/foreign governments
- ☐
- Lack of trust in vaccine manufactures
- ☐
- Religious beliefs
- ☐
- Other
- 3a.
- [V3 = Other]: Specify _____________
- 4i.
- [IF V1 = YES] We understand that you previously had the opportunity to be vaccinated against COVID-19. However, some people’s opinions about vaccination can change over time.
- 4ii.
- [IF V2 = YES] For the next set of questions, we would like you to imagine that you had never received any doses of the COVID-19 vaccine before today.
- 4.
- If an approved vaccine to prevent COVID-19 was available to you today at no cost, would you agree to be vaccinated?’
- Yes
- No
- Not sure/It depends
- 5.
- If a vaccine to prevent COVID-19 was available to you today at no cost, would your decision to be vaccinated depend on which vaccine was available?
- Yes
- No
- 5a.
- [V5 = YES] Which of the following COVID-19 vaccines would you be willing to receive? Read each option, check all that apply
- ☐
- AstraZeneca/Oxford
- ☐
- Pfizer/BioNTech
- ☐
- Moderna
- ☐
- Johnson & Johnson/Janssen
- ☐
- Sinopharm/Chinese National Biotec Group
- ☐
- None of these
- 6.
- [V4 = NO | IT DEPENDS] What are some of the reasons you would not want to be vaccinated? Select all that are mentioned. Do not read specific items, but you can prompt the respondent with “Any other reasons?” Until they have nothing to say.
- Perceived risks of COVID-19
- ☐
- COVID-19 is not dangerous or does not exist
- ☐
- I am not personally at risk of COVID-19
- ☐
- I have already been infected with COVID-19
- COVID-19 vaccine
- ☐
- The COVID-19 vaccine is unsafe or has side effects
- ☐
- The COVID-19 vaccine has not been tested enough
- ☐
- The COVID-19 vaccine is not effective at stopping infection
- ☐
- The COVID-19 vaccine is specifically designed to harm me (e.g., conspiracy theory)
- ☐
- I have concerns about specific type(s) of COVID-19 vaccine
- Trust
- ☐
- Lack of trust in national government
- ☐
- Lack of trust in international donors/foreign governments
- ☐
- Lack of trust in vaccine manufactures
- ☐
- Religious beliefs
- ☐
- Other
- 6a.
- [V6 = Other]: Specify _____________
- 7.
- [V4 = YES|IT DEPENDS] What are the some of reasons you would want to be vaccinated? (Select all that are mentioned. Do not read specific items, but prompt the respondent with “Any other reasons?” until they have nothing to say.)
- Perceived benefits
- ☐
- For my health
- ☐
- For the health of my family
- ☐
- For the health of the community
- ☐
- To stop the COVID-19 pandemic
- Mandates
- ☐
- It is required by my workplace
- ☐
- It is mandated by someone else
- Recommendations
- ☐
- The government or ministry of health recommends it
- ☐
- A healthcare worker recommends it
- ☐
- A friend or family member recommends it
- ☐
- Someone else recommends it
- ☐
- Other
- 7a.
- [V7 = Other]: Specify _____________
- 7b.
- [V7 = Someone else recommends it]: Specify who recommended it: _____________
- 7c.
- [V7 = Someone else mandated it]: Specify who mandated it: _____________
- 8.
- What are your primary sources of COVID-19 vaccines information (Select all that are mentioned. Do not read specific items.)
- ☐
- National government/ministry of health
- ☐
- Health care workers
- ☐
- Social media (Facebook, WhatsApp, Twitter)
- ☐
- Mass media (radio, TV, newspapers)
- ☐
- Employer
- ☐
- Local leaders
- ☐
- Family or friends
- 9.
- How much would you trust each of the following people or institutions to help you decide whether you should obtain a COVID vaccine? Your options are “Strongly distrust,” “Distrust a little”, “Neither trust nor distrust”,“Trust a little”, or “Trust a lot”.
| Strongly Distrust | Distrust a Little | Neither Trust nor Distrust | Trust a Little | Trust a Lot | |
| World Health Organization | |||||
| Regional health authorities (Africa CDC, African Union, PAHO, etc.) | |||||
| The Ministry of Health | |||||
| Facility-based healthcare worker | |||||
| Community health workers | |||||
| Mass media (newspapers, radio, TV, etc.) | |||||
| Social media (Facebook, WhatsApp, Twitter, etc.) | |||||
| Local leaders (context-dependent: religious leaders, healers, mayors, chiefs, etc.) | |||||
| Family or friends |
- 10.
- Do you know where to go to receive a COVID-19 vaccine?
- Yes
- No
- 10a.
- [if 10 = YES] Where would you go to receive a COVID-19 vaccine?
We have finished with our questions about the COVID-19 vaccine. However, before we end, we would like to ask a few questions about the Ebola vaccine.
- E1.
- Have you ever had the opportunity to receive a vaccine for Ebola?
- Yes
- No
- E2.
- [E1 = YES] Have you ever received a vaccine for Ebola?
- Yes
- No
- E3.
- [E2 = YES] How satisfied were you with vaccination process?
- Very dissatisfied
- Dissatisfied
- Neutral
- Satisfied
- Very satisfied
[If E1 = YES] We understand that you previously had the opportunity to be vaccinated against Ebola. However, some people’s opinions about vaccination can change over time.
[If E2 = YES] For the next set of questions, we would like you to imagine that you had never received any doses of the Ebola vaccine before today.
- E4.
- If an approved vaccine to prevent Ebola was available to you today at no cost, would you agree to be vaccinated?’
- Yes
- No
- Not sure/It depends
[If E4 = YES and V4! = Yes] Why would you feel more comfortable receiving a vaccine against Ebola than receiving a vaccine against COVID-19?
[If E4! = YES and V4 = Yes] Why would you feel less comfortable receiving a vaccine against COVID-19 than receiving a vaccine against Ebola?
References
- World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. 2023. Available online: https://covid19.who.int/ (accessed on 24 May 2023).
- World Health Organization (WHO). WHO COVID-19 Health Emergency Dashboard: Sierra Leone Situation. Available online: https://covid19.who.int/region/afro/country/sl (accessed on 16 September 2022).
- Tessema, G.A.; Kinfu, Y.; Dachew, B.A.; Tesema, A.G.; Assefa, Y.; Alene, K.A.; Aregay, A.F.; Ayalew, M.B.; Bezabhe, W.M.; Bali, A.G.; et al. The COVID-19 pandemic and healthcare systems in Africa: A scoping review of preparedness, impact and response. BMJ Glob. Health 2021, 6, e007179. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention (CDC). Benefits of Getting A COVID-19 Vaccine. COVID-19; 2023. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html (accessed on 24 May 2023).
- Gill, I.; Schellekens, P. COVID-19 Is a Developing Country Pandemic. Future Development. 2021. Available online: https://www.brookings.edu/blog/future-development/2021/05/27/covid-19-is-a-developing-country-pandemic/ (accessed on 16 September 2022).
- Ngo, V.M.; Zimmermann, K.F.; Nguyen, P.V.; Huynh, T.L.D.; Nguyen, H.H. How education and GDP drive the COVID-19 vaccination campaign. Arch. Public Health 2022, 80, 171. [Google Scholar] [CrossRef] [PubMed]
- Aschwanden, C. Five reasons why COVID herd immunity is probably impossible. Nature 2021, 591, 520–522. [Google Scholar] [CrossRef] [PubMed]
- Britton, T.; Ball, F.; Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science 2020, 369, 846–849. [Google Scholar] [CrossRef]
- Josephson, A.; Kilic, T.; Michler, J.D. Socioeconomic impacts of COVID-19 in low-income countries. Nat. Hum. Behav. 2021, 5, 557–565. [Google Scholar] [CrossRef]
- Yoo, K.J.; De Francisco Serpa, N.; Gordillo-Tobar, A. Calculating Sub-Saharan Africa’s COVID Vaccination Financing Gap. Investing in Health. 2021. Available online: https://blogs.worldbank.org/health/calculating-sub-saharan-africas-covid-vaccination-financing-gap (accessed on 16 September 2022).
- Solís Arce, J.S.; Warren, S.S.; Meriggi, N.F.; Scacco, A.; McMurry, N.; Voors, M.; Syunyaev, G.; Malik, A.A.; Aboutajdine, S.; Adeojo, O.; et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat. Med. 2021, 27, 1385–1394. [Google Scholar] [CrossRef]
- Allington, D.; McAndrew, S.; Moxham-Hall, V.; Duffy, B. Coronavirus conspiracy suspicions, general vaccine attitudes, trust and coronavirus information source as predictors of vaccine hesitancy among UK residents during the COVID-19 pandemic. Psychol. Med. 2021, 53, 236–247. [Google Scholar] [CrossRef] [PubMed]
- Shekhar, R.; Sheikh, A.B.; Upadhyay, S.; Singh, M.; Kottewar, S.; Mir, H.; Barrett, E.; Pal, S. COVID-19 Vaccine Acceptance among Health Care Workers in the United States. Vaccines 2021, 9, 119. [Google Scholar] [CrossRef] [PubMed]
- Dinga, J.N.; Sinda, L.K.; Titanji, V.P.K. Assessment of Vaccine Hesitancy to a COVID-19 Vaccine in Cameroonian Adults and Its Global Implication. Vaccines 2021, 9, 175. [Google Scholar] [CrossRef] [PubMed]
- Kanyanda, S.; Markhof, Y.; Wollburg, P.; Zezza, A. Acceptance of COVID-19 vaccines in sub-Saharan Africa: Evidence from six national phone surveys. BMJ Open 2021, 11, e055159. [Google Scholar] [CrossRef] [PubMed]
- MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef] [PubMed]
- Wellcome. Wellcome Global Monitor 2018; Wellcome: London, UK, 2019. [Google Scholar]
- Sheku, M.; Clemens, R.; Clemens, S.A.C.; Kangbai, J.B.; Kargbo, I.; Jusu, M.O.; Swaray, I.B. COVID-19 Vaccine Acceptability: A Cross-Sectional Mixed Methods Study in Sierra Leone. In Review. Posted 17 September 2021. Available online: https://www.researchsquare.com/article/rs-625455/v2 (accessed on 1 June 2023).
- Yendewa, S.A.; Ghazzawi, M.; James, P.B.; Smith, M.; Massaquoi, S.P.; Babawo, L.S.; Deen, G.F.; Russell, J.B.; Samai, M.; Sahr, F.; et al. COVID-19 Vaccine Hesitancy among Healthcare Workers and Trainees in Freetown, Sierra Leone: A Cross-Sectional Study. Vaccines 2022, 10, 757. [Google Scholar] [CrossRef] [PubMed]
- Faye, S.L.B.; Krumkamp, R.; Doumbia, S.; Tounkara, M.; Strauss, R.; Ouedraogo, H.G.; Sagna, T.; Mbawah, A.K.; Doumbia, C.O.; Diouf, S.; et al. Factors influencing hesitancy towards adult and child COVID-19 vaccines in rural and urban West Africa: A cross-sectional study. BMJ Open 2022, 12, e059138. [Google Scholar] [CrossRef] [PubMed]
- The World Bank. Sierra Leone. Data. 2021. Available online: https://data.worldbank.org/country/sierra-leone (accessed on 24 May 2023).
- The World Bank. Poverty Headcount Ratio at National Poverty Lines (% of Population)—Sierra Leone. Data. 2023. Available online: https://data.worldbank.org/indicator/SI.POV.NAHC?locations=SL (accessed on 24 May 2023).
- Perez-Escamilla, R.; Bermudez, O.; Buccini, G.S.; Kumanyika, S.; Lutter, C.K.; Monsivais, P.; Victora, C. Nutrition disparities and the global burden of malnutrition. BMJ 2018, 361, k2252. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation (WHO). Sierra Leone 2018 Annual Report. Available online: https://www.afro.who.int/sites/default/files/2019-09/WHO%20Sierra%20Leone%202018%20Annual%20Report.pdf (accessed on 24 May 2023).
- Statistics Sierra Leone (SSL). Sierra Leone 2015 Population and Housing Census; National Analytical Report; October 2017; Statistics Sierra Leone (SSL): Freetown, Sierra Leone, 2017; Available online: https://www.statistics.sl/images/StatisticsSL/Documents/Census/2015/2015_census_national_analytical_report.pdf (accessed on 24 May 2023).
- OCHA Sierra Leone. Sierra Leone: Kono District Profile; OCHA Sierra Leone: Freetown, Sierra Leone, 2015. [Google Scholar]
- Aron, M.B.; Connolly, E.; Vrkljan, K.; Zaniku, H.R.; Nyirongo, R.; Mailosi, B.; Ruderman, T.; Barnhart, D.A.; Partners in Health Cross-Site COVID-19 Cohort Research Network. Attitudes toward COVID-19 Vaccines among Patients with Complex Non-Communicable Disease and Their Caregivers in Rural Malawi. Vaccines 2022, 10, 792. [Google Scholar] [CrossRef] [PubMed]
- Moucheraud, C.; Phiri, K.; Whitehead, H.S.; Songo, J.; Lungu, E.; Chikuse, E.; Phiri, S.; van Oosterhout, J.J.; Hoffman, R.M. Uptake of the COVID-19 vaccine among healthcare workers in Malawi. Int. Health 2023, 15, 77–84. [Google Scholar] [CrossRef] [PubMed]
- Statacorp, L.L.C. Stata Statistical Software, Version 15.1; StataCorp LLC: College Station, TX, USA, 2017. [Google Scholar]
- UNICEF. COVID-19 Vaccines Shipped by COVAX Arrive in Sierra Leone; UNICEF West and Central Africa: Dakar, Senegal, 2021. [Google Scholar]
Figure 1.
(a) COVID-19 vaccine uptake by facility role (N = 2015); (b) intention to vaccinate by facility role (N = 2015).
Figure 1.
(a) COVID-19 vaccine uptake by facility role (N = 2015); (b) intention to vaccinate by facility role (N = 2015).
Figure 2.
Reasons for and against the intention to vaccinate by facility role (N = 2015).
Table 1.
Respondent characteristics by facility role (N = 2015).
| Total | Clinician | Non-Clinical Staff | Outpatient/Patient Caregiver | p-Value | |
|---|---|---|---|---|---|
| N = 2015 | N = 230 | N = 379 | N = 1406 | ||
| Location | <0.001 | ||||
| Koidu Government Hospital | 617 (30.6%) | 71 (30.9%) | 139 (36.7%) | 407 (28.9%) | |
| Wellbody Clinic | 522 (25.9%) | 39 (17.0%) | 99 (26.1%) | 384 (27.3%) | |
| Sewafe Community Health Center | 140 (6.9%) | 13 (5.7%) | 4 (1.1%) | 123 (8.7%) | |
| Konbayedeh Community Health Center | 115 (5.7%) | 5 (2.2%) | 16 (4.2%) | 94 (6.7%) | |
| Lakka Government Hospital | 287 (14.2%) | 50 (21.7%) | 61 (16.1%) | 176 (12.5%) | |
| Kissy Psychiatric Teaching Hospital | 334 (16.6%) | 52 (22.6%) | 60 (15.8%) | 222 (15.8%) | |
| Sex (N = 1994) | <0.001 | ||||
| Female | 1028 (51.6%) | 143 (62.2%) | 107 (28.5%) | 778 (56.0%) | |
| Male | 966 (48.4%) | 87 (37.8%) | 268 (71.5%) | 611 (44.0%) | |
| Age, categorized (N = 2013) | <0.001 | ||||
| 18–24 | 401 (19.9%) | 19 (8.3%) | 40 (10.6%) | 342 (24.4%) | |
| 25–34 | 817 (40.6%) | 94 (40.9%) | 173 (45.6%) | 550 (39.2%) | |
| 35–44 | 518 (25.7%) | 83 (36.1%) | 111 (29.3%) | 324 (23.1%) | |
| 45–54 | 198 (9.8%) | 23 (10.0%) | 43 (11.3%) | 132 (9.4%) | |
| 55–64 | 61 (3.0%) | 9 (3.9%) | 11 (2.9%) | 41 (2.9%) | |
| 65+ | 18 (0.9%) | 2 (0.9%) | 1 (0.3%) | 15 (1.1%) | |
| Level of education (N = 2002) | <0.001 | ||||
| None | 519 (25.9%) | 1 (0.4%) | 56 (14.8%) | 462 (33.1%) | |
| Some primary | 90 (4.5%) | 0 (0.0%) | 16 (4.2%) | 74 (5.3%) | |
| Complete primary | 84 (4.2%) | 1 (0.4%) | 9 (2.4%) | 74 (5.3%) | |
| Some secondary | 540 (27.0%) | 2 (0.9%) | 105 (27.8%) | 433 (31.1%) | |
| Complete secondary | 402 (20.1%) | 39 (17.0%) | 118 (31.2%) | 245 (17.6%) | |
| Post-secondary | 367 (18.3%) | 187 (81.3%) | 74 (19.6%) | 106 (7.6%) | |
| Ethnicity 1 | |||||
| Kono | 771 (38.3%) | 73 (31.7%) | 135 (35.6%) | 563 (40.0%) | 0.027 |
| Krio | 562 (27.9%) | 53 (23.0%) | 98 (25.9%) | 411 (29.2%) | 0.092 |
| Mende | 355 (17.6%) | 89 (38.7%) | 91 (24.0%) | 175 (12.4%) | <0.001 |
| Temne | 266 (13.2%) | 32 (13.9%) | 52 (13.7%) | 182 (12.9%) | 0.880 |
| Limba | 196 (9.7%) | 14 (6.1%) | 44 (11.6%) | 138 (9.8%) | 0.080 |
| Fullah | 162 (8.0%) | 7 (3.0%) | 12 (3.2%) | 143 (10.2%) | <0.001 |
| Mandingo | 162 (8.0%) | 19 (8.3%) | 34 (9.0%) | 109 (7.8%) | 0.730 |
| Other | 104 (5.2%) | 11 (4.8%) | 24 (6.3%) | 69 (4.9%) | 0.520 |
| Loko | 87 (4.3%) | 11 (4.8%) | 17 (4.5%) | 59 (4.2%) | 0.910 |
| Korankoh | 71 (3.5%) | 8 (3.5%) | 9 (2.4%) | 54 (3.8%) | 0.390 |
| Sherbro | 38 (1.9%) | 6 (2.6%) | 11 (2.9%) | 21 (1.5%) | 0.140 |
| Primary source of COVID-19 vaccine information 1 | |||||
| Mass media | 1527 (75.8%) | 194 (84.3%) | 302 (79.7%) | 1031 (73.3%) | <0.001 |
| Family or friends | 1037 (51.5%) | 88 (38.3%) | 188 (49.6%) | 761 (54.1%) | <0.001 |
| National government/Ministry of Health | 898 (44.6%) | 127 (55.2%) | 232 (61.2%) | 539 (38.3%) | <0.001 |
| Social media | 835 (41.4%) | 128 (55.7%) | 220 (58.0%) | 487 (34.6%) | <0.001 |
| Health care workers | 564 (28.0%) | 78 (33.9%) | 136 (35.9%) | 350 (24.9%) | <0.001 |
| Local leaders | 295 (14.6%) | 17 (7.4%) | 50 (13.2%) | 228 (16.2%) | 0.002 |
| Employer | 85 (4.2%) | 19 (8.3%) | 37 (9.8%) | 29 (2.1%) | <0.001 |
1 Respondents could indicate multiple ethnicities and primary sources of information about COVID-19 vaccines.
Table 2.
Uptake and attitudes toward vaccines by COVID-19 vaccination status (N = 2015).
| COVID-19 Vaccination Status | |||||
|---|---|---|---|---|---|
| Total | Fully Vaccinated | Partially Vaccinated | Not Vaccinated 1 | p-Value | |
| N = 2015 | N = 647 | N = 356 | N = 1012 | ||
| Intention to vaccinate against COVID-19 | |||||
| If an approved vaccine to prevent COVID-19 was available to you today at no cost | <0.001 | ||||
| No | 506 (25.1%) | 25 (3.9%) | 36 (10.1%) | 445 (44.0%) | |
| Yes | 1472 (73.1%) | 616 (95.2%) | 312 (87.6%) | 544 (53.8%) | |
| Unsure | 37 (1.8%) | 6 (0.9%) | 8 (2.2%) | 23 (2.3%) | |
| Which of the following COVID-19 vaccines would you be willing to receive? | |||||
| AstraZeneca/Oxford (N = 1499) | 1127 (55.9%) | 412 (63.7%) | 252 (70.8%) | 463 (45.8%) | <0.001 |
| Johnson & Johnson (N = 1499) | 1114 (55.3%) | 426 (65.8%) | 220 (61.8%) | 468 (46.2%) | <0.001 |
| Sinopharm/Chinese National Biotec Group (N = 1499) | 1033 (51.3%) | 353 (54.6%) | 233 (65.4%) | 447 (44.2%) | <0.001 |
| Pfizer/BioNTech (N = 1499) | 900 (44.7%) | 283 (43.7%) | 200 (56.2%) | 417 (41.2%) | <0.001 |
| Moderna (N = 1499) | 896 (44.5%) | 281 (43.4%) | 198 (55.6%) | 417 (41.2%) | <0.001 |
| None of these (N = 605) | 33 (1.6%) | 11 (1.7%) | 7 (2.0%) | 15 (1.5%) | 0.007 |
| Trusted sources of information about the COVID-19 vaccine 2 | |||||
| The Ministry of Health (N = 2008) | 1339 (66.7%) | 508 (78.9%) | 274 (77.2%) | 557 (55.2%) | <0.001 |
| Local leaders (N = 2008) | 1339 (66.7%) | 508 (78.9%) | 274 (77.2%) | 557 (55.2%) | <0.001 |
| Family or friends (N = 2008) | 1339 (66.7%) | 508 (78.9%) | 274 (77.2%) | 557 (55.2%) | <0.001 |
| Facility-based healthcare worker (N = 1938) | 1243 (64.1%) | 466 (74.7%) | 261 (75.4%) | 516 (53.3%) | <0.001 |
| World Health Organization (N = 2011) | 1304 (64.8%) | 480 (74.5%) | 272 (76.6%) | 552 (54.5%) | <0.001 |
| Community health workers (N = 1991) | 1187 (59.6%) | 433 (67.6%) | 256 (73.4%) | 498 (49.8%) | <0.001 |
| Regional health authorities (N = 1977) | 1119 (56.6%) | 395 (61.6%) | 245 (70.2%) | 479 (48.5%) | <0.001 |
| Mass media (N = 1924) | 620 (32.2%) | 179 (29.1%) | 111 (32.8%) | 330 (34.0%) | 0.120 |
| Social media (N = 1985) | 453 (22.8%) | 99 (15.5%) | 81 (22.9%) | 273 (27.5%) | <0.001 |
| Quality of care during COVID-19 vaccination among fully or paritally vaccinated (N = 1003) | |||||
| Did anyone tell you which type of vaccine you would receive? (N = 1002) | 486 (48.5%) | 349 (54.0%) | 137 (38.5%) | N/A | <0.001 |
| Did anyone tell you the timing for your second dose? (N = 996) | 518 (52.0%) | 343 (53.6%) | 175 (49.2%) | N/A | 0.180 |
| Did anyone tell you about possible adverse events following immunization? (N = 989) | 593 (60.0%) | 397 (62.2%) | 196 (55.8%) | N/A | 0.050 |
| Were COVID-19 prevention measures maintained at the vaccination site? (N = 991) | 658 (66.4%) | 435 (68.3%) | 223 (63.0%) | N/A | 0.091 |
| How satisfied were you with COVID-19 vaccination process? (N = 1001) | <0.001 | ||||
| Very dissatisfied | 9 (0.9%) | 5 (0.8%) | 4 (1.1%) | N/A | |
| Dissatisfied | 19 (1.9%) | 4 (0.6%) | 15 (4.2%) | N/A | |
| Neutral | 144 (14.4%) | 76 (11.8%) | 68 (19.2%) | N/A | |
| Satisfied | 603 (60.2%) | 428 (66.3%) | 175 (49.3%) | N/A | |
| Very satisfied | 226 (22.6%) | 133 (20.6%) | 93 (26.2%) | N/A | |
1 Includes both those who had no opportunity to receive the COVID-19 vaccine (N = 986) and those who refused the vaccine (N = 26). 2 Indicates proportion of patients who trust this source a lot.
Table 3.
Predictors of low access to COVID-19 vaccines (no opportunity to be vaccinated) (N = 1974).
Table 3.
Predictors of low access to COVID-19 vaccines (no opportunity to be vaccinated) (N = 1974).
| Univariate | Logistic Regression Model | |||||
|---|---|---|---|---|---|---|
| No Opportunity | Had an Opportunity | p-Value 2 | OR | 95% CI | p-Value 3 | |
| N = 967 | N = 1007 | |||||
| Location | <0.001 | <0.001 | ||||
| Koidu Government Hospital | 230 (23.8%) | 369 (36.6%) | 1.36 | 0.85–2.20 | ||
| Wellbody Clinic | 158 (16.3%) | 347 (34.5%) | 1.11 | 0.68–1.82 | ||
| Sewafe Community Health Center | 87 (9.0%) | 53 (5.3%) | 1.66 | 0.93–2.94 | ||
| Konbayedeh Community Health Center | 54 (5.6%) | 60 (6.0%) | 1.00 | --- | ||
| Lakka Government Hospital | 194 (20.1%) | 92 (9.1%) | 6.45 | 3.76–11.06 | ||
| Kissy Psychiatric Teaching Hospital | 244 (25.2%) | 86 (8.5%) | 8.37 | 4.89–14.33 | ||
| Role at the facility | <0.001 | <0.001 | ||||
| Clinician | 47 (4.9%) | 182 (18.1%) | 1.00 | --- | ||
| Non-clinical staff | 123 (12.7%) | 250 (24.8%) | 1.72 | 1.04–2.86 | ||
| Outpatient/patient caregiver | 797 (82.4%) | 575 (57.1%) | 4.21 | 2.62–6.77 | ||
| Sex | 0.001 | --- | ||||
| Female | 534 (55.2%) | 482 (47.9%) | --- | --- | ||
| Male | 433 (44.8%) | 525 (52.1%) | --- | --- | ||
| Age, categorized (years) | <0.001 | <0.001 | ||||
| 18–24 | 234 (24.2%) | 158 (15.7%) | 4.62 | 3.09–6.93 | ||
| 25–34 | 396 (41.0%) | 409 (40.6%) | 2.66 | 1.88–3.76 | ||
| 35–44 | 229 (23.7%) | 276 (27.4%) | 1.56 | 1.09–2.24 | ||
| ≥45 | 108 (11.2%) | 164 (16.3%) | 1.00 | --- | ||
| Level of education | <0.001 | <0.001 | ||||
| Did not complete primary | 370 (38.3%) | 232 (23.0%) | 3.00 | 1.98–4.55 | ||
| Completed primary | 344 (35.6%) | 270 (26.8%) | 2.02 | 1.35–3.02 | ||
| Completed secondary | 146 (15.1%) | 248 (24.6%) | 1.27 | 0.84–1.93 | ||
| Post-secondary | 107 (11.1%) | 257 (25.5%) | 1.00 | --- | ||
| Ethnicity 1 | ||||||
| Kono | 280 (29.0%) | 477 (47.4%) | <0.001 | 0.71 | 0.56–0.91 | 0.006 |
| Krio | 304 (31.4%) | 253 (25.1%) | 0.002 | --- | --- | --- |
| Mende | 155 (16.0%) | 194 (19.3%) | 0.060 | --- | --- | --- |
| Temne | 168 (17.4%) | 97 (9.6%) | <0.001 | --- | --- | --- |
| Limba | 108 (11.2%) | 80 (7.9%) | 0.015 | --- | --- | --- |
| Fullah | 94 (9.7%) | 66 (6.6%) | 0.010 | --- | --- | --- |
| Mandingo | 69 (7.1%) | 90 (8.9%) | 0.140 | --- | --- | --- |
| Other | 49 (5.1%) | 54 (5.4%) | 0.770 | --- | --- | --- |
| Loko | 51 (5.3%) | 34 (3.4%) | 0.038 | --- | --- | --- |
| Korankoh | 35 (3.6%) | 35 (3.5%) | 0.860 | --- | --- | --- |
| Sherbro | 17 (1.8%) | 19 (1.9%) | 0.830 | --- | --- | --- |
| Primary sources of COVID-19 Information 1 | ||||||
| Mass media | 660 (68.3%) | 831 (82.5%) | <0.001 | 0.71 | 0.54–0.92 | 0.011 |
| Family or friends | 563 (58.2%) | 458 (45.5%) | <0.001 | --- | --- | --- |
| National government/Ministry of Health | 347 (35.9%) | 533 (52.9%) | <0.001 | --- | --- | --- |
| Social media | 273 (28.2%) | 536 (53.2%) | <0.001 | 0.74 | 0.58–0.93 | 0.011 |
| Health care workers | 169 (17.5%) | 385 (38.2%) | <0.001 | 0.44 | 0.34–0.56 | <0.001 |
| Local leaders | 114 (11.8%) | 176 (17.5%) | <0.001 | --- | --- | --- |
| Employer | 15 (1.6%) | 69 (6.9%) | <0.001 | --- | --- | --- |
1 Respondents could indicate multiple ethnicities and primary sources of information about COVID-19 vaccines. 2 Chi-squared or Fisher’s exact tests were used. 3 Wald test was used.
Table 4.
Predictors of poor COVID-19 vaccine acceptability (responded no or unsure to the intention of receiving a COVID-19 vaccine) (N = 1974).
Table 4.
Predictors of poor COVID-19 vaccine acceptability (responded no or unsure to the intention of receiving a COVID-19 vaccine) (N = 1974).
| Univariate | Logistic Regression Model | |||||
|---|---|---|---|---|---|---|
| Do Not Intend to Be Vaccinated (No/Unsure) | Intend to Be Vaccinated | p-Value 2 | OR | 95% CI | p-Value 3 | |
| N = 535 | N = 1439 | |||||
| Location | <0.001 | <0.001 | ||||
| Koidu Government Hospital | 78 (14.6%) | 521 (36.2%) | 4.59 | 1.93–10.90 | ||
| Wellbody Clinic | 110 (20.6%) | 395 (27.4%) | 8.74 | 3.62–21.09 | ||
| Sewafe Community Health Center | 6 (1.1%) | 134 (9.3%) | 1.00 | --- | ||
| Konbayedeh Community Health Center | 37 (6.9%) | 77 (5.4%) | 4.70 | 1.78–12.42 | ||
| Lakka Government Hospital | 155 (29.0%) | 131 (9.1%) | 26.37 | 10.77–64.58 | ||
| Kissy Psychiatric Teaching Hospital | 149 (27.9%) | 181 (12.6%) | 32.90 | 13.78–78.58 | ||
| Sex | 0.380 | |||||
| Female | 284 (53.1%) | 732 (50.9%) | --- | --- | ||
| Male | 251 (46.9%) | 707 (49.1%) | --- | --- | ||
| Age, categorized (years) | 0.580 | 0.009 | ||||
| 18–24 | 116 (21.7%) | 276 (19.2%) | 1.98 | 1.29–3.06 | ||
| 25–34 | 209 (39.1%) | 596 (41.4%) | 1.36 | 0.93–1.97 | ||
| 35–44 | 139 (26.0%) | 366 (25.4%) | 1.17 | 0.79–1.72 | ||
| ≥45 | 71 (13.3%) | 201 (14.0%) | 1.00 | --- | ||
| Level of education | <0.001 | <0.001 | ||||
| Did not complete primary | 197 (36.8%) | 405 (28.1%) | 3.16 | 2.18–4.57 | ||
| Completed primary | 170 (31.8%) | 444 (30.9%) | 1.75 | 1.22–2.50 | ||
| Completed secondary | 92 (17.2%) | 302 (21.0%) | 1.51 | 1.02–2.26 | ||
| Post-secondary | 76 (14.2%) | 288 (20.0%) | 1.00 | --- | ||
| Ethnicity 1 | ||||||
| Kono | 147 (27.5%) | 610 (42.4%) | <0.001 | --- | --- | --- |
| Krio | 260 (48.6%) | 297 (20.6%) | <0.001 | 2.97 | 2.20–4.01 | <0.001 |
| Mende | 99 (18.5%) | 250 (17.4%) | 0.560 | --- | --- | --- |
| Temne | 90 (16.8%) | 175 (12.2%) | 0.007 | --- | --- | --- |
| Limba | 61 (11.4%) | 127 (8.8%) | 0.083 | --- | --- | --- |
| Fullah | 58 (10.8%) | 102 (7.1%) | 0.007 | --- | --- | --- |
| Mandingo | 39 (7.3%) | 120 (8.3%) | 0.450 | --- | --- | --- |
| Other | 29 (5.4%) | 74 (5.1%) | 0.800 | --- | --- | --- |
| Loko | 27 (5.0%) | 58 (4.0%) | 0.320 | --- | --- | --- |
| Korankoh | 18 (3.4%) | 52 (3.6%) | 0.790 | --- | --- | --- |
| Sherbro | 13 (2.4%) | 23 (1.6%) | 0.220 | --- | --- | --- |
| Primary sources of COVID-19 Information 1 | ||||||
| Mass media | 335 (62.6%) | 1156 (80.3%) | <0.001 | 0.65 | 0.50–0.85 | 0.002 |
| Family or friends | 357 (66.7%) | 664 (46.1%) | <0.001 | --- | --- | --- |
| National government/Ministry of Health | 216 (40.4%) | 664 (46.1%) | 0.022 | --- | --- | --- |
| Social media | 163 (30.5%) | 646 (44.9%) | <0.001 | --- | --- | --- |
| Health care workers | 73 (13.6%) | 481 (33.4%) | <0.001 | 0.31 | 0.23–0.42 | <0.001 |
| Local leaders | 77 (14.4%) | 213 (14.8%) | 0.820 | --- | --- | --- |
| Employer | 8 (1.5%) | 76 (5.3%) | <0.001 | --- | --- | --- |
1 Respondents could indicate multiple ethnicities and primary sources of information about COVID-19 vaccines. 2 Chi-squared or Fisher’s exact tests were used. 3 Wald test was used.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Joseph, S.A.; Jerome, J.G.; Boima, F.; Pognon, P.R.; Fejfar, D.; Dibba, Y.; Lavalie, D.; Barrie, M.B.; Oteju, A.; Sheku, M.; et al. Attitudes toward COVID-19 Vaccination: Staff and Patient Perspectives at Six Health Facilities in Sierra Leone. Vaccines 2023, 11, 1385. https://doi.org/10.3390/vaccines11081385
AMA Style
Joseph SA, Jerome JG, Boima F, Pognon PR, Fejfar D, Dibba Y, Lavalie D, Barrie MB, Oteju A, Sheku M, et al. Attitudes toward COVID-19 Vaccination: Staff and Patient Perspectives at Six Health Facilities in Sierra Leone. Vaccines. 2023; 11(8):1385. https://doi.org/10.3390/vaccines11081385
Chicago/Turabian StyleJoseph, Stefanie A., Jean Gregory Jerome, Foday Boima, Pierre Ricard Pognon, Donald Fejfar, Yusupha Dibba, Daniel Lavalie, Mohamed Bailor Barrie, Aramide Oteju, Mohamed Sheku, and et al. 2023. "Attitudes toward COVID-19 Vaccination: Staff and Patient Perspectives at Six Health Facilities in Sierra Leone" Vaccines 11, no. 8: 1385. https://doi.org/10.3390/vaccines11081385
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
